From the ∗Division of Nephrology and Hypertension
†Department of Radiology, Mayo Clinic, Rochester, MN.
Received for publication May 6, 2020; and accepted for publication, after revision, June 23, 2020.
Correspondence to: Lilach O. Lerman, MD, PhD, Division of Nephrology and Hypertension, Mayo Clinic, 200 First St SW, Rochester, MN 55905. E-mail: [email protected].
M.A. and K.J. contributed equally to this work and are listed as co-first authors.
This study was partly supported by the National Institutes of Health grant numbers DK120292, DK104273, DK122734, AG062104, and DK102325.
Conflicts of interest and sources of funding: Dr Lerman receives grant funding from Novo Nordisk and is an advisor to Weijian Technologies and AstraZeneca. The other authors declare that they have no competing interest.
Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.investigativeradiology.com).
